Approaches to Etiotropic Therapy of Covid-19 in Outpatient Patients

Simple item page
dc.creatorA., Mukhtorova Sh.
dc.creatorA. S., Jalilova
dc.date2022-07-05
dc.date.accessioned2023-09-16T00:37:09Z
dc.date.available2023-09-16T00:37:09Z
dc.descriptionThe article presents the results of a post-registration observational study to evaluate the results of early initiation of antiviral therapy in patients with COVID-19 receiving treatment at home. Goal- to evaluate the efficacy and safety of antiviral therapy for the treatment of outpatient patients with coronavirus infection caused by SARS-COV-2. Materials and methods. The study included 200 outpatient patients with COVID-19. According to etiotropic therapy, patients were divided into 3 groups: those who received favipiravir, hydroxychloroquine and those who did not receive antiviral agents. Results. The average time to virus elimination while taking favipiravir was 3 (3.0-5.0) days, among those receiving hydroxychloroquine – 5 (4.0-6.0) days, without antiviral therapy – 8.5 (7.0-10.0) days. Normalization of body temperature occurred faster with favipiravir therapy. Conclusions. Antiviral therapy in outpatient patients with COVID-19 is effective and safe. . Taking favipiravir promotes earlier elimination of the virus, faster normalization of body temperature and a favorable outcome of the disease. Hydroxychloroquine may be prescribed as an alternative antiviral drug to outpatient patients in the absence of a risk of severe course.en-US
dc.formatapplication/pdf
dc.identifierhttps://cejsr.academicjournal.io/index.php/journal/article/view/1433
dc.identifier.urihttps://dspace.umsida.ac.id/handle/123456789/35401
dc.languageeng
dc.publisherPublishing House Education and Science s.r.o.en-US
dc.relationhttps://cejsr.academicjournal.io/index.php/journal/article/view/1433/1357
dc.rightshttps://creativecommons.org/licenses/by/4.0en-US
dc.sourceStředoevropský vědecký bulletin; Vol 26 (2022): July; 19-22cs-CZ
dc.sourceMiddle European Scientific Bulletin; Vol. 26 (2022): July; 19-22en-US
dc.source2694-9970
dc.source10.47494/mesb.2022.26
dc.subjectCOVID-19en-US
dc.subjectSARS-CoV-2en-US
dc.subjectcoronavirus infectionen-US
dc.subjecthydroxychloroquineen-US
dc.subjectfavipiraviren-US
dc.subjectvirus eliminationen-US
dc.titleApproaches to Etiotropic Therapy of Covid-19 in Outpatient Patientsen-US
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
Files
Collections
Middle European Scientific Bulletin